James Chavez
UPS is putting $48 million into 27 temperature-controlled facilities, a move announced Monday that deepens the freight giant's expansion into healthcare logistics. The sites handle short-term storage as shipments transfer between air and ground transport, positioning the company to grab a larger slice of the booming market for cold-stored medicine.
At a Glance
- UPS is spending $48 million on 27 temperature-controlled storage sites worldwide.
- The temperature-sensitive biologics market is valued at $39.1 billion and growing.
- Improper storage causes half of all global vaccine waste, costing $35 billion a year, per the World Health Organization.
- UPS's healthcare portfolio cleared $3 billion in quarterly revenue for the first time in Q1.
- FedEx is chasing the same opportunity, ending fiscal 2024 with roughly $9 billion in healthcare revenue.
Why cold storage is suddenly worth $48 million
The bet here is straightforward. A growing list of medications has to stay cold from the moment they leave a factory until they reach a patient, and any break in that chain can ruin them. Gene and cell therapies, mRNA vaccines and GLP-1 injectables all fall into that category. Get the temperature wrong and the product is worthless.
The numbers behind the risk are sobering. The World Health Organization estimates that temperature failures account for 50% of vaccine waste globally and run up a $35 billion annual bill. That waste is exactly the gap UPS wants to close with facilities built to keep biologics stable during the vulnerable handoffs between planes and trucks.
"This effort—and all of our work in healthcare logistics—extends from a deep understanding that we're doing more than moving packages," said Kate Gutmann, who runs international, healthcare and supply chain solutions for the company. "We are helping patients access the medications and treatments they need."
GLP-1 demand is reshaping the pipeline
One drug class explains a lot of the urgency: GLP-1s. According to KFF data from November 2025, roughly one in eight adults reports taking the medication, whether for diabetes, weight loss or another condition. That kind of uptake forces every link in the supply chain to scale up fast.
Drugmakers are pouring money in to keep pace. Eli Lilly said in March it would invest $3 billion over the coming decade to expand manufacturing in China, much of it aimed at orforglipron, its experimental GLP-1 receptor drug. Demand looks set to climb further. Starting July 1, some Medicare beneficiaries could get GLP-1 prescriptions for $50 a month under a new Centers for Medicare & Medicaid Services program.
Healthcare as a hedge against shaky demand
For freight companies, healthcare offers something most of their business doesn't: stability. People keep seeking treatment even when budgets tighten, which makes medical shipping far less sensitive to economic swings than the rest of the parcel trade.
UPS CEO Carol Tome put it bluntly to Reuters in April. "There have been lots of challenges over the past several years—high inflation, contractions in markets—but healthcare continues to grow," she said. "I would argue that healthcare is pretty recession-proof."
The company has been building toward this for a while. In January it acquired Frigo-Trans and BPL, two European cold-chain logistics outfits. That deal followed the November 2025 purchase of Andlauer Healthcare Group for $1.6 billion. On the first-quarter earnings call in April, Tome noted that the global healthcare portfolio has gained market share every year since 2021 and crossed $3 billion in quarterly revenue for the first time.
How UPS and FedEx stack up in healthcare
| Company | Recent healthcare move | Reported revenue figure |
|---|---|---|
| UPS | $48M into 27 cold-storage sites; acquired Frigo-Trans, BPL and Andlauer | $3B in Q1 healthcare revenue |
| FedEx | Hired a healthcare-focused VP of quality | ~$9B in fiscal 2024 healthcare revenue |
FedEx wants in too
UPS isn't moving alone. FedEx brought on a vice president of quality with global healthcare logistics experience earlier this year and finished fiscal 2024 with about $9 billion in healthcare revenue. The company has been candid that it sees room to grow, especially in pharmaceuticals.
"To attract new business in pharma, where we are currently under-penetrated, we are enhancing our offering to serve the specialized, unique needs of our customers with extreme emphasis on quality," FedEx Chief Customer Officer Brie Carere told investors in March.
Frequently Asked Questions
How much is UPS spending on temperature-controlled facilities?
UPS announced a $48 million investment across 27 temperature-controlled sites designed for short-term storage during transfers between air and ground transport.
How large is the market UPS is targeting?
The temperature-sensitive biologics market is valued at $39.1 billion and continues to expand as demand grows for medications that must be kept cold.
Why are freight companies betting on healthcare?
Healthcare demand tends to be inelastic, meaning people keep seeking treatment even during downturns. That makes medical logistics a steadier business than general parcel shipping when the broader economy weakens.
Which medications require cold storage?
Gene and cell therapies, mRNA vaccines and GLP-1 injectables all need temperature-controlled handling to remain effective.
What comes next
With GLP-1 use climbing and Medicare poised to make some prescriptions cheaper this summer, the volume of cold-chain shipments isn't going to shrink anytime soon. UPS has staked out an early lead through acquisitions and now this facility buildout. FedEx is sharpening its pharma pitch. The race to move the world's most fragile medicine safely is only getting more crowded.
